HELICOBACTER PYLORI-ASSOCIATED CHRONIC GASTRITIS: EPIDEMIOLOGY, DIAGNOSIS AND CHOICE OF ERADICATION THERAPY IN THE SETTING OF HIGH CLARITHROMYCIN RESISTANCE
DOI:
https://doi.org/10.26662/agervw76Keywords:
Helicobacter pylori; chronic gastritis; eradication therapy; antibiotic resistance; clarithromycin; bismuth quadruple therapy; gastric cancer; Uzbekistan.Abstract
Aim. To summarize current evidence on the epidemiology, diagnosis and treatment of Helicobacter pylori-associated chronic gastritis, taking into account regional data on H. pylori antibiotic resistance in Central Asia and Uzbekistan. Material and methods. International and national consensus documents (Maastricht VI/Florence, ACG 2024, Kyoto consensus, Taipei Global Consensus II, ESPGHAN/NASPGHAN 2023, etc.), systematic reviews, meta-analyses and randomized trials published predominantly in 2016–2026 and indexed in PubMed/MEDLINE, Scopus, eLIBRARY.ru and Google Scholar, as well as regional studies from Central Asian countries, were analysed. Results. The global prevalence of infection among adults has declined to 43–44% but remains high in Central Asia (about 70%). H. pylori causes chronic active gastritis in all infected individuals and is the main cause of gastric cancer, which is the leading cause of cancer death in Uzbekistan. For primary diagnosis in adults without indications for endoscopy, the ¹4C-urea breath test and the monoclonal stool antigen test are preferred; when endoscopy is indicated, biopsy-based methods with gastritis staging according to OLGA/OLGIM are used. According to a multicentre study, clarithromycin resistance of H. pylori in Uzbekistan reaches 41–45%, which precludes empirical use of clarithromycin-containing regimens. Fourteen-day bismuth quadruple therapy is the first-line regimen of choice; clarithromycin- and levofloxacin-containing regimens are appropriate when susceptibility is confirmed. Conclusion. National surveillance of H. pylori antibiotic resistance and implementation in Uzbekistan of a strategy based on bismuth quadruple therapy and mandatory confirmation of eradication are needed.Downloads
Published
2026-11-20
Issue
Section
Articles
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
HELICOBACTER PYLORI-ASSOCIATED CHRONIC GASTRITIS: EPIDEMIOLOGY, DIAGNOSIS AND CHOICE OF ERADICATION THERAPY IN THE SETTING OF HIGH CLARITHROMYCIN RESISTANCE. (2026). JournalNX - A Multidisciplinary Peer Reviewed Journal, 12(11), 21-34. https://doi.org/10.26662/agervw76



















